Kinetics of silica nanoparticles in the human placenta
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Kinetics of silica nanoparticles in the human placenta. / Poulsen, Marie Sønnegaard; Mose, Tina; Maroun, Lisa Leth; Mathiesen, Line; Knudsen, Lisbeth E.; Rytting, Erik.
In: Nanotoxicology, Vol. 9, No. Supplement 1, 2015, p. 79-86.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Kinetics of silica nanoparticles in the human placenta
AU - Poulsen, Marie Sønnegaard
AU - Mose, Tina
AU - Maroun, Lisa Leth
AU - Mathiesen, Line
AU - Knudsen, Lisbeth E.
AU - Rytting, Erik
PY - 2015
Y1 - 2015
N2 - The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 µg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10(-6) ± 1.56 × 10(-6) cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.
AB - The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 µg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10(-6) ± 1.56 × 10(-6) cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.
U2 - 10.3109/17435390.2013.812259
DO - 10.3109/17435390.2013.812259
M3 - Journal article
C2 - 23742169
VL - 9
SP - 79
EP - 86
JO - Nanotoxicology
JF - Nanotoxicology
SN - 1743-5390
IS - Supplement 1
ER -
ID: 137757810